- For QC teams: the letter raises concerns about complete, contemporaneous raw data.
- For QA: it puts Quality Unit authority and CAPA effectiveness under scrutiny.
- For companies using contract laboratories: it reinforces FDA’s position that contractors operate as extensions of the manufacturer’s own facility.
FDA Flags “Testing Into Compliance” in Auriga’s OOS Investigations
FDA inspected Auriga’s Bengaluru laboratory from February 4 to 6, 2026. Investigators found microbial test records with missing raw-data entries even though summary reports contained final plate counts. Auriga said some samples were not intended for the U.S. market, but FDA rejected that distinction because the laboratory uses one quality system and one set of procedures for U.S. and non-U.S. testing.
FDA also cited OOS investigations in which failed results were followed by repeated testing, instrument changes, or retain-sample testing before passing results were accepted. FDA described repeating tests until a passing result is obtained and then disregarding OOS results without scientific justification as “testing into compliance.”
Auriga Warning Letter Exposes Deeper Quality Unit and Data Integrity Gaps
FDA requested assessments of laboratory practices, documentation systems, OOS investigations, CAPA, analyst competencies, and Quality Unit authority. It also requested an independent retrospective review of OOS results for U.S. products covering the previous three years.
The FDA findings point to connected weaknesses across laboratory documentation, OOS investigations, Quality Unit oversight, and CAPA effectiveness, making these four areas the most immediate priorities for quality teams to review.
| Area | FDA Concern | Immediate Focus |
|---|---|---|
|
Laboratory Data |
Incomplete records |
Review raw-data controls |
|
OOS Investigations |
Repeated testing |
Reassess invalidated results |
|
Quality Unit |
Weak oversight |
Strengthen governance |
|
CAPA |
Inadequate actions |
Verify effectiveness |
Specialist question: If a contract laboratory obtains passing results only after repeated retesting, should a sponsor challenge the investigation first or broaden the review to potentially affected batches and methods?
What QA and QC Teams Should Review After FDA’s Auriga Findings
Quality teams should verify that records are complete and contemporaneous, reassess OOS investigations based on invalidated results, confirm that CAPA addresses supported root causes, and ensure the Quality Unit has adequate authority and resources. Sponsors using external laboratories should also assess whether similar practices could affect testing performed for their products. These actions follow directly from the remediation FDA requested.
Auriga Faces 15-Day FDA Response Window; Reinspection Risk Remains
Auriga must respond to FDA within 15 business days of receiving the letter. FDA said it may withhold approval of applications or supplements listing the facility until violations are addressed and compliance is confirmed. The agency may also reinspect the site and warned that unresolved violations could lead to refusal of admission for affected articles tested there.
How Pharma Teams Can Strengthen QMS After Serious FDA Findings
Zamann Pharma’s Quality Management System service supports pharmaceutical teams with CAPA, deviations, audits, and everyday quality-system activities. Teams facing similar findings can explore this support when hands-on help is needed to strengthen QMS execution and oversight.
Source: FDA